Sanara MedTech Inc.

Good morning, ladies and gentlemen, and welcome to the Sonara MedTech Incorporated second quarter 2022 earnings and business update. At this time, all participants have been placed on a listen-only mode, and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Mr. Callum Nichols, Investor Relations. Callum, over to you.

Thank you, and good morning, everyone. I'd like to welcome you to Cenera MedTech's earnings conference call for the quarter ended June 30th, 2022. We issued our earnings release yesterday afternoon, and I would like to also highlight that we've posted today's deck on the investor relations page of our website. This supplemental deck, as well as a copy of the earnings release and the form 10-Q for the quarter ended June 30th are available on this page. We will reference this information in our remarks today. We expect today's prepared comments from Ron Nixon, Executive Chairman, Zach Fleming, Chief Executive Officer, and Mike McNeil, Chief Financial Officer, to last approximately 15 minutes to allow time for Q&A. Certain statements in this conference call, in our press release, and in our supplemental deck include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For more information, about the risk and uncertainties involving forward-looking statements and factors that could cause actual results to vary materially from those projected or implied by forward-looking statements, please see our most recent annual report on Form 10-K and our Form 10-Q for the quarter. Now I'd like to turn the call over to Ron.

Thank you, Callan, and good morning, everyone. In the second quarter of 2022, Sonera generated $9.7 million in revenue, representing a 54% increase from the prior year period. In addition to it being a record revenue quarter, it was also the first quarter during which the company generated $3 million of revenue in all three months of the quarter. Company had a net loss of $3.3 million in the quarter. Mike will go into further detail, but our loss when compared to the same period the previous year was impacted by higher SG&A expenses, which increased $3.9 million, as well as higher R&D costs, which increased $1 million, primarily related to our merger with Precision Healing and several other new development projects. In the second quarter, we completed our merger with Precision Healing, where we acquired the remaining ownership of the company. Zach will go into more detail later in the call. But we believe that the technology currently under development and precision healing will be a key component of our strategy to offer a comprehensive wound and dermatology solution for Medicare Advantage, at-risk payers, and other types of healthcare at-risk models. Subsequent to the end of the quarter, we completed our acquisition of Cyndia Biologics. Zach will also go into more detail, but we believe this acquisition added a significant portfolio of advanced biologic products that are complementary to our current surgical product offering. In addition, we believe the acquisition will expand our ability to provide new health systems and more comprehensive suite of surgical products. Now I ask Zach Fleming to discuss our accomplishments in more detail.